Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

ASTELLAS PHARMA INC (4503)
Mes dernières consult.
Most popular
Report
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Astellas Pharma : Transfer of Distribution Rights for Targocid® and Maalox®

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/09/2011 | 04:10am CET

Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo; Representative Director and President: Jez Moulding) announced that Astellas Pharma will transfer the rights to distribute the injectable antibiotics Targocid® (generic name: teicoplanin) and the treatment for peptic ulcer and gastritis Maalox® (generic name: dried aluminum hydroxide gel and magnesium hydroxide) to sanofi-aventis effective on January 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract.

<Products for which distribution rights will be transferred>

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTELLAS PHARMA INC
01/19 ASTELLAS PHARMA : Research Data from Astellas Pharma Update Understanding of Med..
01/19 ASTELLAS PHARMA : Reports Summarize Central Nervous System Agents Findings from ..
01/19 ASTELLAS PHARMA : New Pelvic Pain Study Findings Have Been Reported by Investiga..
01/15 AMGEN : Astellas Pharma Inc - Repatha SC Injection 420 mg Auto Mini Doser Launch..
01/12 ASTELLAS PHARMA : Submits Supplemental New Drug Application for Approval of Addi..
01/12 ASTELLAS PHARMA : Repatha® SC Injection 420 mg Auto Mini Doser Launched in Japan..
01/11 ASTELLAS PHARMA : Researchers from Astellas Pharma Report New Studies and Findin..
01/11 AMGEN : Astellas BioPharma K.K. - Application for Marketing Approval Submitted f..
01/11 ASTELLAS PHARMA : Submits Supplemental New Drug Application for Approval of Addi..
01/09 ASTELLAS PHARMA : Application for Marketing Approval Submitted for Bispecific CD..
More news
News from SeekingAlpha
01/10 Astellas Pharma (ALPMY) Presents At 36th Annual J.P. Morgan Healthcare Confer..
2017 'Safer' Dividend Healthcare Gainers Glaxo, Pfizer & Medical Facilities Are Ta..
2017 Astellas Pharma acquiring Mitobridge for $225M
2017 3 THINGS IN BIOTECH YOU SHOULD LEARN : November 21, 2017
2017 YOUR DAILY PHARMA SCOOP : Valeant Remains Risky, Novartis's Kisqali, Tesaro Tumb..
Financials ( JPY)
Sales 2018 1 289 B
EBIT 2018 220 B
Net income 2018 178 B
Finance 2018 368 B
Yield 2018 2,60%
P/E ratio 2018 15,33
P/E ratio 2019 14,34
EV / Sales 2018 1,93x
EV / Sales 2019 1,87x
Capitalization 2 862 B
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 1 548  JPY
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Yoshihiko Hatanaka President, CEO & Representative Director
Chikashi Takeda Chief Financial Officer
Mitsunori Matsuda Senior Executive Officer & President-Technology
Yoshiro Miyokawa Representative Director & Executive Vice President
Hironobu Yasuda Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC-4.55%25 854
JOHNSON & JOHNSON5.20%395 886
NOVARTIS0.61%227 592
PFIZER2.65%220 189
ROCHE HOLDING LTD.-5.40%211 135
MERCK AND COMPANY10.24%167 132